Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude pour évaluer l'efficacité et l'innocuité de JNJ-77242113 par rapport au placebo et à l'ustekinumab chez les participants avec un psoriasis de plaque modéré à sévère (ICONIC-ASCEND)

2 novembre 2026 mis à jour par: Janssen Research & Development, LLC

Une étude active contrôlée par le comparateur actif multicentrique, randomisée, en double aveugle, contrôlée par placebo et contrôlée par un comparateur pour évaluer l'efficacité et l'innocuité de JNJ-77242113

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

752

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Augsburg, Allemagne, 86179
        • Klinikum Augsburg
      • Bad Bentheim, Allemagne, 48455
        • Fachklinik Bad Bentheim
      • Berlin, Allemagne, 10789
        • ISA - Interdisciplinary Study Association GmbH
      • Bonn, Allemagne, 53127
        • Universitatsklinikum Bonn
      • Bramsche, Allemagne, 49565
        • Studienzentrum an der Hase GbR
      • Darmstadt, Allemagne, 64283
        • Rosenpark Research GmbH
      • Dresden, Allemagne, 01307
        • Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
      • Friedrichshafen, Allemagne, 88045
        • Derma-Study-Center Friedrichshafen GmbH
      • Kiel, Allemagne, 24105
        • Universitaetsklinikum Schleswig Holstein Campus Kiel
      • Langenau, Allemagne, 89129
        • Studienzentrum Dr Schwarz Germany
      • Mahlow, Allemagne, 15831
        • Dermatologie Mahlow
      • Mainz, Allemagne, 55128
        • Gemeinschaftspraxis Dres. Quist
      • Münster, Allemagne, 48149
        • Universitaetsklinikum Muenster
      • Witten, Allemagne, 58453
        • Hautarztpraxis
      • Barrio Gral Paz Cba Capital, Argentine, X5000
        • Consultora Integral de Salud SRL
      • Buenos Aires, Argentine, B1643CRO
        • Instituto Medico De Alta Complejidad (IMAC)
      • Buenos Aires, Argentine, C1417EYG
        • Mindout Research
      • Buenos Aires, Argentine, C1425
        • Instituto de Neumonologia y Dermatologia
      • CABA, Argentine, C1061AAS
        • CIPREC
      • CABA, Argentine, C1199ABB
        • Hospital Italiano de Buenos Aires
      • CABA, Argentine, C1055AAO
        • Buenos Aires Skin
      • CABA, Argentine, C1056ABH
        • Investigaciones Medicas IMOBA SRL
      • CABA, Argentine, C1128
        • Mautalen Salud e Investigacion
      • Caba, Argentine, C1122AAF
        • Halitus Instituto Medico S.A. - Dermatologia y Estetica
      • Rosario, Argentine, S2000DBS
        • Instituto De Especialidades De La Salud SRL
      • San Fernando, Argentine, B1646
        • MR Medicina Reumatologica
      • San Miguel de Tucumán, Argentine, T4000
        • Instituto de Investigaciones Medicas Tucuman
      • Clayton, Australie, 3168
        • Monash Medical Centre
      • Coorparoo, Australie, 4151
        • Cornerstone Dermatology
      • Greenslopes, Australie, 4120
        • Veracity Clinical Research
      • Kogarah, Australie, 2217
        • Premier Specialists
      • Melbourne, Australie, 3004
        • The Alfred Hospital
      • Melbourne, Australie, 3050
        • Royal Melbourne Hospital
      • Mitcham, Australie, 3132
        • ISHI dermatology
      • Westmead, Australie, 2145
        • Westmead Hospital
      • Brussels, Belgique, 1090
        • UZ Brussel
      • Ghent, Belgique, 9000
        • Ghent University Hospital
      • Ghent, Belgique, 9000
        • AZ St. Lucas
      • Leuven, Belgique, 3000
        • Universitair Ziekenhuis Leuven
      • Liège, Belgique, 4000
        • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
      • Maldegem, Belgique, 9990
        • Dermatologie Maldegem
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada, A1E 1V4
        • Skincare Studio Inc Dermatology Clinical Trials
    • Ontario
      • Ajax, Ontario, Canada, L1S7K8
        • CCA Medical Research Corporation
      • Barrie, Ontario, Canada, L4M 7G1
        • SimcoDerm Medical and Surgical Dermatology Centre
      • Hamilton, Ontario, Canada, L8N 1Y2
        • Dermatrials Research
      • London, Ontario, Canada, N6A 5R9
        • Lovegrove Dermatology
      • Markham, Ontario, Canada, L3P 1X3
        • Lynderm Research Inc.
      • Waterloo, Ontario, Canada, N2J 1C4
        • Alliance Clinical Trials
    • Quebec
      • Montreal, Quebec, Canada, H2X 2V1
        • Innovaderm Research Inc.
      • Québec, Quebec, Canada, G1W 4R4
        • The Centre de recherche Saint-Louis
      • Aalborg, Danemark, 9100
        • Aalborg Sygehus Syd
      • Aarhus, Danemark, 8200
        • Aarhus University Hospital
      • Hellerup, Danemark, 2900
        • Gentofte Hospital
      • København NV, Danemark, 2400
        • Bispebjerg Hospital
      • Odense, Danemark, 5000
        • Odense University Hospital
      • Roskilde, Danemark, 4000
        • Sjællands University hospital
      • Alicante, Espagne, 03010
        • Hosp. Gral. Univ. Dr. Balmis
      • Barakaldo, Espagne, 48902
        • Hosp. Univ. de Cruces
      • Barcelona, Espagne, 08036
        • Hosp. Clinic de Barcelona
      • Granada, Espagne, 18016
        • Hosp. Univ. San Cecilio
      • Madrid, Espagne, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Espagne, 28006
        • Hosp. Univ. de La Princesa
      • Madrid, Espagne, 28002
        • Grupo Dermatologico Y Estetico Pedro Jaen
      • Manises, Espagne, 46940
        • Hosp. de Manises
      • Santiago Compostela, Espagne, 15706
        • Hosp. Clinico Univ. de Santiago
      • Seville, Espagne, 41009
        • Hosp. Virgen Macarena
      • Seville, Espagne, 41014
        • Hosp. Ntra. Sra. de Valme
      • Valencia, Espagne, 46026
        • Hosp. Univ. I Politecni La Fe
      • Villajoyosa, Espagne, 03570
        • Hosp. de La Marina Baixa
      • Zaragoza, Espagne, 50009
        • Hosp. Clinico Univ. Lozano Blesa
      • Zaragoza, Espagne, 50009
        • Hosp. Univ. Miguel Servet
      • Budapest, Hongrie, 1036
        • Obudai Egeszsegugyi Centrum Kft
      • Budapest, Hongrie, 1152
        • Uno Medical Trials Ltd.
      • Debrecen, Hongrie, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Debrecen, Hongrie, 4031
        • Derma-B Kft
      • Gyula, Hongrie, 5700
        • Synexus Magyarorszag Kft
      • Gyöngyös, Hongrie, 3200
        • Gyongyosi Bugat Pal Korhaz
      • Hódmezővásárhely, Hongrie, 6800
        • Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
      • Kaposvár, Hongrie, 7400
        • Somogy Varmegyei Kaposi Mor Oktato Korhaz
      • Kecskemét, Hongrie, 6000
        • Bacs-kiskun Megyei Korhaz
      • Szolnok, Hongrie, 5000
        • Allergo-Derm Bakos Kft.
      • Veszprém, Hongrie, 8200
        • Medmare Egeszsegugyi Es Szolgaltato Bt.
      • Feldkirch, L'Autriche, 6800
        • LKH Feldkirch
      • Linz, L'Autriche, 4020
        • Kepler Universitatsklinikum GmbH
      • Sankt Pölten, L'Autriche, 3100
        • Universtitatsklinikum St Poelten
      • Vienna, L'Autriche, 1090
        • Allgemeines Krankenhaus der Stadt Wien
      • Guimarães, Le Portugal, 4835 044
        • Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
      • Leiria, Le Portugal, 2410 197
        • Unidade Local De Saude Da Regiao De Leiria Epe
      • Lisbon, Le Portugal, 1169 050
        • Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
      • Lisbon, Le Portugal, 1998 018
        • Hosp. Cuf Descobertas
      • Porto, Le Portugal, 4099 001
        • Ulssa Hosp. Santo Antonio
      • Bialystok, Pologne, 15 375
        • Specderm Poznanska sp j
      • Bialystok, Pologne, 15-351
        • Osteo-Medic s.c A. Racewicz, J Supronik
      • Elblag, Pologne, 82 300
        • Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
      • Katowice, Pologne, 40 568
        • Care Clinic Sp z o o
      • Krakow, Pologne, 30 002
        • Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
      • Lodz, Pologne, 90-265
        • Dermed Centrum Medyczne Sp z o o
      • Olsztyn, Pologne, 10-117
        • Etyka Osrodek Badan Klinicznych
      • Poznan, Pologne, 60 529
        • SOLUMED Centrum Medyczne
      • Skierniewice, Pologne, 96 100
        • Velocity Nova Sp z o o
      • Warsaw, Pologne, 02 661
        • Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
      • Warsaw, Pologne, 02 953
        • Klinika Ambroziak Dermatologia
      • Wroclaw, Pologne, 52 416
        • Centrum Medyczne Oporow
      • Wroclaw, Pologne, 51 685
        • WroMedica I Bielicka A Strzalkowska s c
      • Dudley, Royaume-Uni, DY1 2HQ
        • Dudley Group NHS Foundation Trust
      • Harrow, Royaume-Uni, HA1 3UJ
        • London North West University Healthcare NHS Trust
      • Kings Lynn, Royaume-Uni, PE30 4ET
        • The Queen Elizabeth Hospital NHS Foundation Trust
      • London, Royaume-Uni, SE1 9RT
        • Guys and St Thomas NHS Foundation Trust
      • Reading, Royaume-Uni, RG1 5AN
        • Royal Berkshire Hospital
      • Salford, Royaume-Uni, M6 8HD
        • Salford Royal Hospital
      • Southampton, Royaume-Uni, So166yd
        • University Hospital Southampton
      • Wakefield, Royaume-Uni, WF1 4DG
        • Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital
    • Alabama
      • Birmingham, Alabama, États-Unis, 35244
        • Cahaba Research Inc
    • California
      • Encinitas, California, États-Unis, 92024
        • California Dermatology & Clinical Research Institute
      • Encino, California, États-Unis, 91436
        • T Joseph Raoof Md Inc
      • Fountain Valley, California, États-Unis, 92708
        • First OC Dermatology
      • Oceanside, California, États-Unis, 92056
        • Dermatologist Medical Group of North County, Inc.
      • Rocklin, California, États-Unis, 95765
        • NorCal Clinical Research
      • Sacramento, California, États-Unis, 95815
        • Integrative Skin Science and Research
      • San Diego, California, États-Unis, 92103
        • MedDerm Associates
      • Santa Ana, California, États-Unis, 92701
        • Southern California Dermatology
      • Sylmar, California, États-Unis, 91342
        • Olive View-UCLA Education & Research Institute
    • Connecticut
      • Farmington, Connecticut, États-Unis, 06030
        • University of Conn Health Center
    • Florida
      • Miami, Florida, États-Unis, 33155
        • Bioclinical Research Alliance Inc.
      • Miami, Florida, États-Unis, 33126
        • Driven Research LLC
      • Ocala, Florida, États-Unis, 34470
        • Renstar Medical Research
      • Tampa, Florida, États-Unis, 33613
        • Forcare Clinical Research Inc
    • Georgia
      • Alpharetta, Georgia, États-Unis, 30022
        • Hamilton Research LLC
    • Illinois
      • Skokie, Illinois, États-Unis, 60076
        • Northshore Medical Group
    • Indiana
      • Plainfield, Indiana, États-Unis, 46168
        • Indiana Clinical Trial Center
    • Iowa
      • Iowa City, Iowa, États-Unis, 52242
        • University of Iowa
    • Kentucky
      • Bowling Green, Kentucky, États-Unis, 42104
        • Equity Medical
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02111
        • Tufts Medical Center
      • Brighton, Massachusetts, États-Unis, 02135
        • Metro Boston Clinical Partners
    • Michigan
      • Caledonia, Michigan, États-Unis, 49316
        • The Derm Institute of West Michigan
      • Detroit, Michigan, États-Unis, 48202
        • Henry Ford Hospital
      • Fort Gratiot, Michigan, États-Unis, 48059
        • Hamzavi Dermatology
      • Troy, Michigan, États-Unis, 48084
        • Somerset Skin Centre
    • Minnesota
      • New Brighton, Minnesota, États-Unis, 55112
        • Minnesota Clinical Study Center
    • Missouri
      • Kirksville, Missouri, États-Unis, 63501
        • Cleaver Dermatology
      • Saint Joseph, Missouri, États-Unis, 64506
        • MediSearch Clinical Trials
    • New York
      • New York, New York, États-Unis, 10075
        • Sadick Research Group
      • New York, New York, États-Unis, 10028
        • Mount Sinai Doctors Dermatology
    • North Carolina
      • Wilmington, North Carolina, États-Unis, 28405
        • Wilmington Dermatology Center
    • Ohio
      • Boardman, Ohio, États-Unis, 44512
        • Optima Research
      • Mayfield Heights, Ohio, États-Unis, 44124
        • Apex Dermatology Mayfield Heights
    • Oregon
      • Portland, Oregon, États-Unis, 97210
        • Oregon Dermatology and Research Center
      • Portland, Oregon, États-Unis, 97201
        • Oregon Medical Research Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19114
        • Clinical Research Philadelphia
      • Pittsburgh, Pennsylvania, États-Unis, 15213
        • UPMC Department of Dermatology
    • South Dakota
      • Rapid City, South Dakota, États-Unis, 57702
        • Health Concepts
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37211
        • Advanced Research Experts PLLC
    • Texas
      • Arlington, Texas, États-Unis, 76011
        • Arlington Research Center, Inc.
      • Dallas, Texas, États-Unis, 75231
        • Modern Research Associates PLLC
      • Houston, Texas, États-Unis, 77004
        • Center for Clinical Studies 1
      • San Antonio, Texas, États-Unis, 78218
        • Texas Dermatology and Laser Specialists
      • San Antonio, Texas, États-Unis, 78213
        • Progressive Clinical Research
      • Webster, Texas, États-Unis, 77598
        • Center for Clinical Studies
    • Utah
      • West Valley City, Utah, États-Unis, 84120
        • Kalo Clinical Research
    • Washington
      • Mill Creek, Washington, États-Unis, 98012
        • Frontier Derm Partners CRO, LLC

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

12 ans et plus (Enfant, Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
  • Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
  • Total psoriasis area and severity index (PASI) >=12 at screening and baseline
  • Total investigator global assessment (IGA) >=3 at screening and baseline
  • Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

  • Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
  • Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
  • Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
  • Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Arm 1: JNJ 77242113

Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind.

JNJ-77242113 will be administered orally.

Matching placebo will be administered subcutaneously.

Comparateur placebo: Arm 2: Placebo

Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104.

JNJ-77242113 will be administered orally.

Matching placebo will be administered subcutaneously.

Matching placebo will be administered orally.

Comparateur actif: Arm 3: Ustekinumab

Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28.

JNJ-77242113 will be administered orally.

Matching placebo will be administered orally.

Ustekinumab will be administered subcutaneously.

Autres noms:
  • STELARA
  • ONTC 1275

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
Délai: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Délai: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 16

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
Délai: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Délai: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
Délai: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
Délai: Week 28

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
Délai: Week 28

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
Délai: Week 28

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 28
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
Délai: Week 16

PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
Délai: Week 16

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 16
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: Up to Week 108

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product & is medically important.

Up to Week 108
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
Délai: Week 16

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease.

Week 16
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
Délai: Baseline up to Week 16

DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Baseline up to Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
Délai: Week 16

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Week 16
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
Délai: Baseline up to Week 16

BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.

Baseline up to Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
Délai: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
Délai: Baseline up to Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
Délai: Baseline up to Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
Délai: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
Délai: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
Délai: Baseline up to Week 28

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
Délai: Week 28

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
Délai: Baseline up to Week 16

BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.

Baseline up to Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
Délai: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
Délai: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Délai: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 16

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

15 avril 2025

Achèvement primaire (Réel)

17 novembre 2025

Achèvement de l'étude (Estimé)

20 août 2027

Dates d'inscription aux études

Première soumission

11 avril 2025

Première soumission répondant aux critères de contrôle qualité

11 avril 2025

Première publication (Réel)

18 avril 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

3 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 77242113PSO3006
  • 77242113PSO3006 (Autre identifiant: Janssen Research & Development, LLC)
  • 2024-515706-77-00 (Identificateur de registre: EUCT number)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner